VANDA PHARMACEUTICALS INC. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
VANDA PHARMACEUTICALS INC. (VNDA) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $36.19 million for the 6-month period ending 2015-06-30, per its 10-Q filed 2015-07-31.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2015-07-31
- 2015-06-30: Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month $36.19M.
- 2014-06-30: Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month $1.69M.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month |
|---|---|
| 2015-06-30 | $36.19M 10-Q · filed 2015-07-31 |
| 2014-06-30 | $1.69M 10-Q · filed 2015-07-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |